Department of Neurology, University Medical Center, RWTH Aachen, Aachen, Germany.
PLoS One. 2012;7(11):e47452. doi: 10.1371/journal.pone.0047452. Epub 2012 Nov 5.
Polyglutamine (polyQ) diseases represent a neuropathologically heterogeneous group of disorders. The common theme of these disorders is an elongated polyQ tract in otherwise unrelated proteins. So far, only symptomatic treatment can be applied to patients suffering from polyQ diseases. Despite extensive research, the molecular mechanisms underlying polyQ-induced toxicity are largely unknown. To gain insight into polyQ pathology, we performed a large-scale RNAi screen in Drosophila to identify modifiers of toxicity induced by expression of truncated Ataxin-3 containing a disease-causing polyQ expansion. We identified various unknown modifiers of polyQ toxicity. Large-scale analysis indicated a dissociation of polyQ aggregation and toxicity.
多聚谷氨酰胺(polyQ)疾病代表了一组神经病理学异质性紊乱。这些疾病的共同主题是在原本不相关的蛋白质中存在延长的 polyQ 片段。到目前为止,只能对患有 polyQ 疾病的患者进行对症治疗。尽管进行了广泛的研究,但 polyQ 诱导毒性的分子机制在很大程度上仍是未知的。为了深入了解 polyQ 病理学,我们在果蝇中进行了大规模的 RNAi 筛选,以鉴定由含有致病 polyQ 扩展的截断 Ataxin-3 表达诱导的毒性的修饰剂。我们鉴定了各种未知的 polyQ 毒性修饰剂。大规模分析表明 polyQ 聚集和毒性的分离。